Journal article

The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network

Mohammad S Hossain, Robert J Commons, Nicholas M Douglas, Kamala Thriemer, Bereket H Alemayehu, Chanaki Amaratunga, Anupkumar R Anvikar, Elizabeth A Ashley, Puji BS Asih, Verena I Carrara, Chanthap Lon, Umberto D'Alessandro, Timothy ME Davis, Arjen M Dondorp, Michael D Edstein, Rick M Fairhurst, Marcelo U Ferreira, Jimee Hwang, Bart Janssens, Harin Karunajeewa Show all



BACKGROUND: There is a high risk of Plasmodium vivax parasitaemia following treatment of falciparum malaria. Our study aimed to quantify this risk and the associated determinants using an individual patient data meta-analysis in order to identify populations in which a policy of universal radical cure, combining artemisinin-based combination therapy (ACT) with a hypnozoitocidal antimalarial drug, would be beneficial. METHODS AND FINDINGS: A systematic review of Medline, Embase, Web of Science, and the Cochrane Database of Systematic Reviews identified efficacy studies of uncomplicated falciparum malaria treated with ACT that were undertaken in regions coendemic for P. vivax between 1 January..

View full abstract


Awarded by Australian NHMRC Senior Research Fellowship

Awarded by Bill & Melinda Gates Foundation

Awarded by Australian Centre for Research Excellence on Malaria Elimination (ACREME) - NHMRC of Australia

Funding Acknowledgements

MSH is supported by a Clinical Research and Development Fellowship scheme from TDR, the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. RJC is supported by a Postgraduate Australian National Health and Medical Research Council (NHMRC) Scholarship and a RACP NHMRC Kincaid-Smith Scholarship. RNP is a Wellcome Trust Senior Fellow in Clinical Science (200909). JAS is funded by an Australian NHMRC Senior Research Fellowship (1104975). KT is a CSL Centenary Fellow and received support by the Asia Pacific Malaria Elimination Network (APMEN) and OPRA clinical trial funding, supported by the Bill & Melinda Gates Foundation (INV-007122). PD is funded by Tropical Network Fund, Nuffield Department of Clinical Medicine, University of Oxford. WWARN is funded by Bill and Melinda Gates Foundation and Exxon Mobil Foundation grants. TMED is supported by an Australian Medical Research Future Fund Practitioner Fellowship. This work was supported by the Australian Centre for Research Excellence on Malaria Elimination (ACREME), funded by the NHMRC of Australia (1134989) and in part by the Intramural Research Program of the NIH, National Institute of Allergy and Infectious Diseases. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.